<p>Vanguard Group Inc.（萬得集團）在第四季度增持了 Inari Medical, Inc.（納斯達克股票代碼：NARI - 免費報告）的持股比例，根據該公司最近向證券交易委員會（SEC）提交的文件。該公司在該時期收購了額外的 325,586 股股票後，擁有了 5,038,292 股公司股票。截至最近一次提交給 SEC 的文件，Vanguard Group Inc.擁有 Inari Medical 價值 3.27086 億美元的股份，佔公司總股本的 8.69%。</p>
<p>獲取 <strong>Inari Medical</strong> 的警報：</p>
<ul>
<li>5 家增長三位數收益的醫療股</li>
</ul>
<p>其他對沖基金和其他機構投資者最近也增加或減少了對該公司的持股。挪威中央銀行在第四季度收購了 Inari Medical 股票的新頭寸，價值約 2,949,100 美元。Brown Advisory Inc.在第四季度將其對 Inari Medical 的持股增加了 17.6%。Brown Advisory Inc.現在擁有 1,702,113 股公司股票，價值 1.10501 億美元，比購買時增加了 255,182 股。Clearbridge Investments LLC 在第四季度購入了 Inari Medical 的新頭寸，價值約 1,147,900 美元。Point72 Europe London LLP 在第四季度將其對 Inari Medical 的持股增加了 91.8%。Point72 Europe London LLP 現在擁有 332,202 股公司股票，價值 2,156,700 美元，比購買時增加了 158,997 股。最後，Principal Financial Group Inc.在第四季度增加了對 Inari Medical 的持股，增幅為 23.4%。Principal Financial Group Inc.現在擁有 567,266 股公司股票，價值 3,682,700 美元，比上一季度增加了 107,622 股。對沖基金和其他機構投資者擁有公司股份的 90.98%。</p>
<h2>內部人員活動</h2>
<p>據相關消息，首席財務官 Mitch C. Hill 在 4 月 12 日星期五進行了一筆交易，賣出了公司股票 6,000 股。這些股票的平均價格為 40.96 美元，交易總額為 245,760.00 美元。交易完成後，首席財務官在公司中擁有 181,294 股股票，價值約 7,425,802.24 美元。該交易已在向 SEC 提交的法律文件中披露，可通過 SEC 網站訪問。此外，首席財務官 Mitch C. Hill 在 4 月 12 日星期五進行了一筆交易，賣出了公司股票 6,000 股。這些股票的平均價格為 40.96 美元，交易總額為 245,760.00 美元。交易完成後，首席財務官直接持有公司 181,294 股股票，價值 7,425,802.24 美元。該交易已在提交給證券交易委員會的文件中披露，可通過 SEC 網站訪問。此外，首席執行官 Andrew Hykes 在 5 月 28 日星期二進行了一筆交易，賣出了公司股票 3,000 股。這些股票的平均價格為 50.00 美元，交易總額為 150,000.00 美元。交易完成後，首席執行官在公司中持有 465,474 股股票，價值約 2,327,370.00 美元。此次交易的披露可在此處找到。內部人員在過去 90 天內共出售了價值 7,514,191 美元的公司股票共 161,224 股。公司內部人員目前持有公司股份的 10.60%。</p>
<h2>分析師設定新的價格目標</h2>
<ul>
<li>在業績大幅增長後，Integer 可能將走向新高</li>
</ul>
<p>一些研究分析師最近發佈了關於 NARI 股票的報告。Truist Financial 將 Inari Medical 的目標股價從 61.00 美元降至 52.00 美元，並在 3 月 22 日的報告中為該公司設定了 “持有” 評級。Canaccord Genuity Group 將 Inari Medical 的目標股價從 75.00 美元降至 55.00 美元，並在 5 月 1 日的報告中為該公司設定了 “買入” 評級。Needham &amp; Company LLC 將 Inari Medical 的目標股價從 72.00 美元降至 57.00 美元，並在 5 月 1 日的研究報告中為該股票設定了 “買入” 評級。富國銀行將 Inari Medical 的目標股價從 100.00 美元降至 84.00 美元，並在 5 月 1 日的研究報告中為該公司設定了 “超重” 評級。最後，Piper Sandler 將 Inari Medical 的目標股價從 55.00 美元降至 50.00 美元，並在 5 月 1 日的報告中為該公司設定了 “中性” 評級。兩位研究分析師給予該股票持有評級，五位給予買入評級。根據 MarketBeat 的數據，Inari Medical 的平均評級為 “中等買入”，平均目標股價為 65.71 美元。</p>
<p><strong>查看我們對 Inari Medical 的最新股票分析</strong></p>
<h2>Inari Medical 股價上漲 2.5%</h2>
<ul>
<li>3 家新上市公司的強勁股票圖表</li>
</ul>
<p>NARI 股票週五開盤價為 48.15 美元。Inari Medical, Inc.的 12 個月最低價為 36.73 美元，最高價為 71.85 美元。公司的 50 天移動平均價格為 45.22 美元，其兩百天移動平均價格為 50.59 美元。該公司的市值為 28 億美元，市盈率為-117.44，貝塔係數為 1.02。</p>
<p>Inari Medical（納斯達克股票代碼：NARI - 獲取免費報告）最近公佈了其截至 4 月 30 日星期二的財報。公司報告該季度每股收益（EPS）為（0.26）美元，低於分析師預期的（0.11）美元。Inari Medical 的淨利潤率為-4.54%，淨資產收益率為-1.65%。該季度公司營收為 1.4319 億美元，超過分析師預期的 1.3832 億美元。研究分析師平均預測，Inari Medical, Inc.本財年每股盈利將達到-0.41 美元。</p>
<h2>關於 Inari Medical（免費報告）</h2>
<p>Inari Medical, Inc 在美國為特定疾病狀態製造微創、新穎和基於導管的機械血栓切除裝置和配件。該公司提供 ClotTriever 系統，旨在核心、捕獲和清除大血管中的大血栓，用於治療深靜脈血栓形成和外周血栓; FlowTriever 系統，一種大孔徑導管式抽吸和機械血栓切除系統，用於清除外周血管中的大血栓，治療肺栓塞和其他複雜的靜脈血栓栓塞病例; InThrill 系統用於治療小血管血栓; LimFlow 系統用於患有慢性威脅性肢體缺血且無適當的血管內或外科再灌注選擇以及面臨重大截肢風險的患者。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們比 Inari Medical 更喜歡的股票</li>
<li>什麼是 WallStreetBets 以及他們瞄準哪些股票？</li>
<li>高通股票：儘管波動性，但以人工智能為動力的增長</li>
<li>什麼是看跌期權成交量？</li>
<li>Salesforce 股票：會議總結，人工智能重點和預測</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>CAVA 是否過度估值？仔細研究這隻高飛股</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFSSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFSSQ"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 喬·拜登的終結（來自 Banyan Hill Publishing）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk5"/></p>
<h2>現在是否值得投資 $1,000 到 Inari Medical？</h2>
<p>在考慮 Inari Medical 之前，您會想聽聽這個。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單... 而 Inari Medical 不在其中。</p>
<p>雖然 Inari Medical 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

NARI

<p>根據最近向美國證券交易委員會提交的文件顯示，Vanguard Group Inc.在第四季度增加了對 Inari Medical, Inc.的持股比例達 6.9%。其他對沖基金和機構投資者也增加了對該公司的持股。內部人士在過去 90 天內大量出售了公司股票。分析師們對 Inari Medical 發佈了各種價格目標和評級</p>

<p>Vanguard Group Inc. lifted its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 6.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,038,292 shares of the company's stock after acquiring an additional 325,586 shares during the period. Vanguard Group Inc. owned 8.69% of Inari Medical worth $327,086,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p>
<div class="lb-trans"><p>Vanguard Group Inc.（萬得集團）在第四季度增持了 Inari Medical, Inc.（納斯達克股票代碼：NARI - 免費報告）的持股比例，根據該公司最近向證券交易委員會（SEC）提交的文件。該公司在該時期收購了額外的 325,586 股股票後，擁有了 5,038,292 股公司股票。截至最近一次提交給 SEC 的文件，Vanguard Group Inc.擁有 Inari Medical 價值 3.27086 億美元的股份，佔公司總股本的 8.69%。</p>
</div><p>Get <strong>Inari Medical</strong> alerts:</p>
<ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>Inari Medical</strong> 的警報：</p>
<ul>
<li>5 家增長三位數收益的醫療股</li>
</ul>
</div><p>Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Inari Medical in the fourth quarter valued at about $29,491,000. Brown Advisory Inc. increased its holdings in Inari Medical by 17.6% in the 4th quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company's stock worth $110,501,000 after buying an additional 255,182 shares during the period. Clearbridge Investments LLC purchased a new position in Inari Medical during the 4th quarter worth approximately $11,479,000. Point72 Europe London LLP lifted its stake in Inari Medical by 91.8% during the 4th quarter. Point72 Europe London LLP now owns 332,202 shares of the company's stock valued at $21,567,000 after acquiring an additional 158,997 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in shares of Inari Medical by 23.4% in the 4th quarter. Principal Financial Group Inc. now owns 567,266 shares of the company's stock valued at $36,827,000 after acquiring an additional 107,622 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company's stock.</p>
<div class="lb-trans"><p>其他對沖基金和其他機構投資者最近也增加或減少了對該公司的持股。挪威中央銀行在第四季度收購了 Inari Medical 股票的新頭寸，價值約 2,949,100 美元。Brown Advisory Inc.在第四季度將其對 Inari Medical 的持股增加了 17.6%。Brown Advisory Inc.現在擁有 1,702,113 股公司股票，價值 1.10501 億美元，比購買時增加了 255,182 股。Clearbridge Investments LLC 在第四季度購入了 Inari Medical 的新頭寸，價值約 1,147,900 美元。Point72 Europe London LLP 在第四季度將其對 Inari Medical 的持股增加了 91.8%。Point72 Europe London LLP 現在擁有 332,202 股公司股票，價值 2,156,700 美元，比購買時增加了 158,997 股。最後，Principal Financial Group Inc.在第四季度增加了對 Inari Medical 的持股，增幅為 23.4%。Principal Financial Group Inc.現在擁有 567,266 股公司股票，價值 3,682,700 美元，比上一季度增加了 107,622 股。對沖基金和其他機構投資者擁有公司股份的 90.98%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部人員活動</h2>
</div><p>In related news, CFO Mitch C. Hill sold 6,000 shares of the company's stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the transaction, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CFO Mitch C. Hill sold 6,000 shares of the business's stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $40.96, for a total transaction of $245,760.00. Following the completion of the sale, the chief financial officer now directly owns 181,294 shares in the company, valued at $7,425,802.24. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the firm's stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the transaction, the chief executive officer now owns 465,474 shares in the company, valued at approximately $23,273,700. The disclosure for this sale can be found here. Insiders have sold a total of 161,224 shares of company stock worth $7,514,191 over the last 90 days. 10.60% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>據相關消息，首席財務官 Mitch C. Hill 在 4 月 12 日星期五進行了一筆交易，賣出了公司股票 6,000 股。這些股票的平均價格為 40.96 美元，交易總額為 245,760.00 美元。交易完成後，首席財務官在公司中擁有 181,294 股股票，價值約 7,425,802.24 美元。該交易已在向 SEC 提交的法律文件中披露，可通過 SEC 網站訪問。此外，首席財務官 Mitch C. Hill 在 4 月 12 日星期五進行了一筆交易，賣出了公司股票 6,000 股。這些股票的平均價格為 40.96 美元，交易總額為 245,760.00 美元。交易完成後，首席財務官直接持有公司 181,294 股股票，價值 7,425,802.24 美元。該交易已在提交給證券交易委員會的文件中披露，可通過 SEC 網站訪問。此外，首席執行官 Andrew Hykes 在 5 月 28 日星期二進行了一筆交易，賣出了公司股票 3,000 股。這些股票的平均價格為 50.00 美元，交易總額為 150,000.00 美元。交易完成後，首席執行官在公司中持有 465,474 股股票，價值約 2,327,370.00 美元。此次交易的披露可在此處找到。內部人員在過去 90 天內共出售了價值 7,514,191 美元的公司股票共 161,224 股。公司內部人員目前持有公司股份的 10.60%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<ul>
<li>After blowout earnings, Integer may be headed to new highs</li>
</ul>
<div class="lb-trans"><h2>分析師設定新的價格目標</h2>
<ul>
<li>在業績大幅增長後，Integer 可能將走向新高</li>
</ul>
</div><p>Several research analysts recently issued reports on NARI shares. Truist Financial reduced their target price on shares of Inari Medical from $61.00 to $52.00 and set a &#34;hold&#34; rating for the company in a report on Friday, March 22nd. Canaccord Genuity Group decreased their price objective on Inari Medical from $75.00 to $55.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, May 1st. Needham &amp; Company LLC lowered their target price on Inari Medical from $72.00 to $57.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, May 1st. Wells Fargo &amp; Company reduced their price target on Inari Medical from $100.00 to $84.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, May 1st. Finally, Piper Sandler decreased their price target on Inari Medical from $55.00 to $50.00 and set a &#34;neutral&#34; rating for the company in a report on Wednesday, May 1st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Inari Medical has an average rating of &#34;Moderate Buy&#34; and an average price target of $65.71.</p>
<div class="lb-trans"><p>一些研究分析師最近發佈了關於 NARI 股票的報告。Truist Financial 將 Inari Medical 的目標股價從 61.00 美元降至 52.00 美元，並在 3 月 22 日的報告中為該公司設定了 “持有” 評級。Canaccord Genuity Group 將 Inari Medical 的目標股價從 75.00 美元降至 55.00 美元，並在 5 月 1 日的報告中為該公司設定了 “買入” 評級。Needham &amp; Company LLC 將 Inari Medical 的目標股價從 72.00 美元降至 57.00 美元，並在 5 月 1 日的研究報告中為該股票設定了 “買入” 評級。富國銀行將 Inari Medical 的目標股價從 100.00 美元降至 84.00 美元，並在 5 月 1 日的研究報告中為該公司設定了 “超重” 評級。最後，Piper Sandler 將 Inari Medical 的目標股價從 55.00 美元降至 50.00 美元，並在 5 月 1 日的報告中為該公司設定了 “中性” 評級。兩位研究分析師給予該股票持有評級，五位給予買入評級。根據 MarketBeat 的數據，Inari Medical 的平均評級為 “中等買入”，平均目標股價為 65.71 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Inari Medical</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Inari Medical 的最新股票分析</strong></p>
</div><h2>Inari Medical Trading Up 2.5 %</h2>
<ul>
<li>3 Newly Public Companies With Strong Charts Post-IPO</li>
</ul>
<div class="lb-trans"><h2>Inari Medical 股價上漲 2.5%</h2>
<ul>
<li>3 家新上市公司的強勁股票圖表</li>
</ul>
</div><p>Shares of NARI stock opened at $48.15 on Friday. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $71.85. The business's 50 day moving average is $45.22 and its two-hundred day moving average is $50.59. The company has a market capitalization of $2.80 billion, a P/E ratio of -117.44 and a beta of 1.02.</p>
<div class="lb-trans"><p>NARI 股票週五開盤價為 48.15 美元。Inari Medical, Inc.的 12 個月最低價為 36.73 美元，最高價為 71.85 美元。公司的 50 天移動平均價格為 45.22 美元，其兩百天移動平均價格為 50.59 美元。該公司的市值為 28 億美元，市盈率為-117.44，貝塔係數為 1.02。</p>
</div><p>Inari Medical (NASDAQ:NARI - Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.15). Inari Medical had a negative net margin of 4.54% and a negative return on equity of 1.65%. The business had revenue of $143.19 million for the quarter, compared to analysts' expectations of $138.32 million. On average, research analysts predict that Inari Medical, Inc. will post -0.41 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Inari Medical（納斯達克股票代碼：NARI - 獲取免費報告）最近公佈了其截至 4 月 30 日星期二的財報。公司報告該季度每股收益（EPS）為（0.26）美元，低於分析師預期的（0.11）美元。Inari Medical 的淨利潤率為-4.54%，淨資產收益率為-1.65%。該季度公司營收為 1.4319 億美元，超過分析師預期的 1.3832 億美元。研究分析師平均預測，Inari Medical, Inc.本財年每股盈利將達到-0.41 美元。</p>
</div><h2>About Inari Medical (Free Report)</h2>
<div class="lb-trans"><h2>關於 Inari Medical（免費報告）</h2>
</div><p>Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.</p>
<div class="lb-trans"><p>Inari Medical, Inc 在美國為特定疾病狀態製造微創、新穎和基於導管的機械血栓切除裝置和配件。該公司提供 ClotTriever 系統，旨在核心、捕獲和清除大血管中的大血栓，用於治療深靜脈血栓形成和外周血栓; FlowTriever 系統，一種大孔徑導管式抽吸和機械血栓切除系統，用於清除外周血管中的大血栓，治療肺栓塞和其他複雜的靜脈血栓栓塞病例; InThrill 系統用於治療小血管血栓; LimFlow 系統用於患有慢性威脅性肢體缺血且無適當的血管內或外科再灌注選擇以及面臨重大截肢風險的患者。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Inari Medical</li>
<li>What Is WallStreetBets and What Stocks Are They Targeting?</li>
<li>Qualcomm Stock: AI-Powered Growth Despite Volatility</li>
<li>What is Put Option Volume?</li>
<li>Salesforce Stock: Meeting Recap, AI Focus, and Forecast</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>Is CAVA Overextended? A Closer Look at This High-Flying Stock</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>五隻我們比 Inari Medical 更喜歡的股票</li>
<li>什麼是 WallStreetBets 以及他們瞄準哪些股票？</li>
<li>高通股票：儘管波動性，但以人工智能為動力的增長</li>
<li>什麼是看跌期權成交量？</li>
<li>Salesforce 股票：會議總結，人工智能重點和預測</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>CAVA 是否過度估值？仔細研究這隻高飛股</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TkFSSQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NARI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ The END of Joe Biden (From Banyan Hill Publishing)(Ad)</p>
<div class="lb-trans"><p>→ 喬·拜登的終結（來自 Banyan Hill Publishing）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTk5" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8599&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Inari Medical right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 $1,000 到 Inari Medical？</h2>
</div><p>Before you consider Inari Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Inari Medical 之前，您會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴客户現在購買的股票清單... 而 Inari Medical 不在其中。</p>
</div><p>While Inari Medical currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Inari Medical 目前在分析師中有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Inari Medical 公司（NASDAQ:NARI）的股票被先鋒集團公司收購